Robert James Peach,Joseph Naemura,Peter S. Linsley,Jurgen Bajorath
申请号：
US14289715
公开号：
US09758565B2
申请日:
2014.05.29
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
